The challenge of the 'C' in CML.
Leader, Myeloproliferative Diseases Program Member, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 489, New York, NY 10065, USA. Electronic address: maurom@mskcc.org.
Michael J
MJ
Mauro
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D008297:Male; D010349:Patient Compliance / Q000523:psychology*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011788:Quality of Life; D012737:Sex Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate